CELSCI Corporation reported QQ1 2025 results with no revenue and a substantial net loss driven by high R&D and operating expenses. R&D expenses totaled $4.43 million and general and administrative costs were $2.46 million, contributing to a total operating expense of $5.90 million and an EBITDA of -$5.91 million. The company posted a net loss of -$7.07 million or -$0.11 per share on 65.33 million weighted-average shares. Cash burn from operations amounted to -$4.14 million in the period, with free cash flow of -$4.17 million. At quarter-end, CELSCI held $4.61 million in cash and equivalents, and reported net debt of $6.47 million against total debt of $11.09 million. The balance sheet shows meaningful long-lived assets (PPE of $15.94 million) and a large accumulated deficit (-$521.08 million), underscoring the ongoing need for external financing to support R&D activity and pipeline advancement.
Looking ahead, the company continues to de-risk its lead program Multikine (phase III in head and neck cancer) and LEAPS-related candidates, but there is no disclosed near-term revenue trajectory or formal guidance in the QQ1 filing. Management commentary is not provided in the available transcript dataset, limiting insight into strategic prioritization beyond the published financials. The runway remains contingent on access to capital markets or collaboration/cunding arrangements, as funded R&D remains the primary driver of value. Investors should monitor clinical milestones, potential data readouts, and any strategic collaborations that could extend the company’s liquidity runway and provide a pathway toward eventual commercialization.